Abstract
Interest in drug overdosage has changed in recent years, because of the extension of drug abuse to all segments of society, the advent of new drugs with specific new actions, the widespread availability of serum drug concentrations, and the emphasis being placed on toxicology by the relatively new field of Emergency Medicine. Misuse of new therapeutic agents has resulted in new types of overdoses requiring new treatments. Since most overdoses are not life threatening, good results may be obtained in many cases without making a diagnosis. However, severe and unusual cases necessitate specific diagnosis and treatment. Toxicology results have shown that mistakes occur when the diagnosis is made on clinical grounds only. Establishing a preliminary diagnosis and providing rational therapy requires a working knowledge of clinical pharmacology, including specific information about the actions of the various drugs, their important chemical and kinetic properties, and their toxic manifestations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Reed CE, Driggs MF, Foote CC: Acute barbiturate intoxication: a study of 300 cases based on a physiologic system of classification of the severity of the intoxication. Ann Intern Med 37: 290, 1954.
Matthew H, Lawson A AH: Acute barbiturate poisoning—a review of two years’ experience. Q J Med 35: 539–552, 1966.
Teasdale G, Jennett B: Assessment of coma and impaired consciousness—a practical scale. Lancet 2: 81–84, 1974.
McCarron MM, Schulze BW, Walberg CB, Thompson GA, Ansari A: Short-acting barbiturate overdosage—correlation of intoxication score with serum barbiturate concentration. JAMA 248: 55–61, 1982.
Simpson D, Reilly P: Paediatric coma scale. Lancet 2: 450, 1982.
Tandberg D, Sklar D: Effect of tachypnea on the estimation of body temperature by an oral thermometer. N Engl J Med 308: 945–946, 1983.
Goldfrank L, Osborn H: Rainbow urine. Hosp Pract 3: 22–26, 1978.
Lewis JM, Klein-Schwartz W, Benson BE, et al.: Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 138: 944–946, 1984.
Greenberg MI, Roberts JR, Baskin SI: Endotracheal naloxone reversal of morphine-induced respiratory depression in rabbits. Ann Emerg Med 9: 289–292, 1980.
Tandberg D, Abercrombie D: Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 11: 443–445, 1982.
Chen HL: Naloxone in shock and toxic coma. Am J Emerg Med 2: 444–452, 1984.
Andree RA: Sudden death following naloxone administration. Anesth Analg 59: 782–784, 1980.
Azar I, Turndorf H: Severe hypertension and mul¬tiple atrial premature contractions following naloxone administration. Anesth Analg 58: 524–525, 1979.
Tanaka GY: Hypertensive reaction to naloxone. JAMA 228: 25–26, 1974.
Michaelis LL, Hickey PR, Clark TA, et al.: Ventricular irritability associated with the use of naloxone. Ann Thorac Surg 18: 608–614, 1974.
Mannelli M, Maggi M, DeFeo ML, et al.: Naloxone administration releases catecholamines. New Engl J Med 308: 654–655, 1983.
Slovin CM, Bachvarov HL: Heated inhalation treatment of hypothermia. Am J Emerg Med 2: 533–536, 1984.
McCarron MM: The use of toxicology tests in emergency room diagnosis. J Analyt Toxicol 7: 131–135, 1983.
Beveridge GW, Lawson AAH: Occurrence of bullous lesions in acute barbiturate intoxication. Br Med J 1: 835–837, 1965.
Mandy S, Akerman AB: Characteristic traumatic skin lesions in drug-induced coma. JAMA 213: 253–256, 1970.
Schanker LS: Absorption of drugs from the rat colon. J Pharmacol Exp Ther 126: 282, 1959.
Mark LC: Pharmacokinetics of barbiturates. In Matthew H (ed): Acute Barbiturate Poisoning. Excepta Medica, Amsterdam, pp 75–83, 1971.
Study RE, Barker JL: Cellular mechanisms of benzodiazepine action. JAMA 247: 2147–2151, 1982.
Walberg CB: An ultraviolet spectrophotometric procedure for differentiating and quantitation of barbiturates. Clin Toxicol 18: 879–885, 1981.
Berg MJ, Berlinger WG, Goldberg MJ, et al.: Acceleration of the body clearance of phénobarbital by oral activated charcoal. N Engl J Med 307: 642–644, 1982.
King K, England JF: Chloral hydrate (Noctec) overdose. Med J Austral 6: 260, 1983.
Information from manufacturer, Squibb Company, 1984.
Gleich GJ, Mongan ES, Vaules DW: Esophageal stricture following chloral hydrate poisoning. JAMA 201: 266–267, 1967.
Stalker NE, Gambertoglio JG, Fukumitsu CJ, et al.: Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. J Clin Pharmacol 18: 136–142, 1978.
Marshall AJ: Cardiac arrhythmias caused by chloral hydrate. Br Med J 2: 994, 1977.
Gustafson A, Svensson SE, Ugander L: Cardiac arrhythmias in chloral hydrate poisoning. Acta Med Scand 201: 227–230, 1977.
Vellar IDA, Richardson JP, Doyle JC, Keating M: Gastric necrosis: a rare complication of chloral hydrate intoxication. Br J Surg 59: 317–319, 1972.
Health A, Delin K, Eden E, et al.: Hemoperfusion with Amberlite resin in the treatment of self-poi- soning. Acta Med Scand 207: 455, 1980.
Baselt RC: Disposition of toxic drugs and chemicals in man, 2nd ed. Biomedical Publications, Davis, California, 1982.
Information from manufacturer, Abbott Company, 1984.
Fairman RP, Glauser FL, Falls R: Increases in lung lymph and albumin clearance with ethchlorvynol. J Appl Physiol 50: 1151–1155, 1981.
Glauser FL, Smith WR, Caldwell A, et al.: The effects of ethchlorvynol on pulmonary alveolar membrane permeability. Am Rev Resp Dis 116: 901–906, 1977.
Van Swearingen P: Placidyl and pulmonary edema. Ann Intern Med 84: 614–615, 1976.
Rosenthal R, Brown JM: Placidyl and pulmonary effects. Ann Intern Med 85: 126, 1976.
Self TM, Fountain FF, Dunnebacke R, et al.: Intravenous ethchlorvynol-induced pulmonary edema. Drug Intell Clin Pharm 13: 96–99, 1979.
Burton WN, Vender J, Shapiro BA: Adult respiratory distress syndrome after placidyl abuse. Crit Care Med 8: 48–49, 1980.
Klock JC: Hemolysis and pancytopenia in eth¬chlorvynol overdose. Ann Intern Med 81: 131–132, 1974.
Brodin MB, Redmond WJ: Bullous eruption due to ethchlorvynol. J Cutan Path 7: 326–329, 1980.
Lynn RI, Honig CL, Jatlow PI, Kliger AS: Resin hemoperfusion for treatment of ethchlorvynol overdose. Ann Intern Med 91: 549–553, 1979.
Benowitz N, Abolin C, Toxer T, et al.: Resin hemoperfusion in ethchlorvynol overdose. Clin Pharmacol Ther 27: 236–242, 1980.
Hammond KB, Rumack BH, Rodgerson DE: Blood ethanol. JAMA 226: 63–64, 1973.
Bogusz M, Peck J, Stasko W: Comparative studies on the rate of ethanol elimination in acute poisoning and in controlled conditions. J For Sci 22: 446–451, 1977.
Goodman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, 1980.
Jeffries DB, Flanagan RJ, Volans GN: Reversal of ethanol-induced coma with naloxone. Lancet 1: 308–309, 1980.
Shramek JJ: Loads [Letter]. N Engl J Med 305: 231, 1982.
Hansen AR, Kennedy KA, Ambre JJ, Fischer LJ: Glutethimide poisoning. A metabolite contributes to morbidity and mortality. N Engl J Med 292: 250, 1975.
Rosenbaum JL, Kramer MS, Raja R: Resin hemoperfusion for acute drug intoxication. Arch Intern Med 136: 263, 1976.
Rotschafer JC, Foleyh C, Zaske D: Glutethimide overdose: clinical and kinetic observations of glutethimide and a metabolite. Minn Med 63: 145–147, 1980.
Baselt RC, Cravey RH: A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids. J Analyt Toxicol 1: 81–103, 1977.
Information from manufacturer, Wyeth Company, 1984.
Blumberg AG, Rosett GHL, Dobrow A: Severe hypotensive reactions following meprobamate overdosage. Ann Intern Med 51: 607, 1959.
Scott PAL, Grimshaw L, Molony HMP: Severe hypotensive crisis following treatment with meprobamate. Arch Intern Med 100: 484–486, 1957.
Jenis EH, Payne RJ, Goldbaum LR: Acute mepro¬bamate poisoning. A fatal case following a lucid interval. JAMA 207: 361–362, 1969.
Schwartz HS: Acute meprobamate poisoning with gastrotomy and removal of drug-containing mass. N Engl J Med 295: 1177–1178, 1976.
Dyment PC, Curtis DD, Gourich GE: Meprobamate poisoning treated with peritoneal dialysis. J Ped 67: 124, 1965.
Maddock RK, Bloomer HA: Meprobamate over¬dosage. Evaluation of its severity and methods of treatment. JAMA 201: 999–1003, 1967.
Hoy WE, Rivero A, Marin MG, Rieders F: Resin hemoperfusion for treatment of massive meprobamate overdose. Ann Intern Med 93: 455–456, 1980.
WHO Review Group: Use and abuse of benzodiazepines. Bull World Health Organization 61: 551–562, 1983.
Hayes SL, Pablo G, Radomski T, Palmer RF: Ethanol and oral diazepam absorption. N Engl J Med 296: 186, 1977.
Ninan PT, Insel TM, Cohen RM, et al.: Benzodiazepine receptor-mediated experimental “anxiety” in primates. Science 218: 1332–1334, 1982.
Petursson H, Lader MH: Withdrawal from long- term benzodiazepine treatment. Br Med J 283: 643–645, 1981.
Finkle BS, McCloskey KL, Goodman LS: Diazepam and drug-associated deaths. JAMA 242: 429–434, 1979.
Avant GR, Speeg KV, Freemon FR, Schenker S, Berman ML: Physostigmine reversal of diazepam-induced hypnosis: a study in human volunteers. Ann Intern Med 91: 53–55, 1979.
Darragh A, Lambe R, Brick I: Reversal of benzodiazepine-induced sedation by intravenous Ro 15–1788. Lancet 2: 1042, 1981.
Information from manufacturer, Roche Company, 1984.
Lion JR, Azcarate CL, Koepke HH: “Paradoxical rage reactions” during psychotropic medication. Dis Nerv Syst 36: 557–558, 1975.
Karch FE: Rage reaction associated with clorazepate dipotassium. Ann Intern Med 81: 61–62, 1979.
McBay AJ: Chemical findings in poisonings. N Engl J Med 274: 1257, 1966.
Cate JC, Jatlow PI: Chlordiazepoxide overdose: interpretation of serum drug concentrations. Clin Toxicol 6: 553–561, 1973.
Hollister LE, Montzenbecker FP, Degan RL: Withdrawal reactions from chlordiazepoxide (Librium). Psychopharmacology 2: 63, 1961.
Richman S, Harris RD: Acute pulmonary edema associated with Librium abuse. Radiology 103: 57–58, 1972.
Browne TR: Clonazepam. New Engl J Med 299: 812–816, 1978.
Welch TR, Rumack BH, Hammond K: Clonazepam overdose resulting in cyclic coma. Clin Toxicol 10: 433–436, 1977.
Barnett AM: Treatment of epilepsy with clonazepam (Ro 5-4023). South Afr Med J 47: 1683–1686, 1973.
Bladin PF: The use of clonazepam as an anticonvulsant: clinical evaluation. Med J Austral 1: 683–688, 1973.
Edwards VE, Eadie MJ: Clonazepam: a clinical study of its effectiveness as an anticonvulsant. Proc Austral Assoc Neurol 10: 61–66, 1973.
Pach VD: The dangers of diazepam, a street drug. New Engl J Med 290: 807, 1974.
Divoli M, Greenblatt DJ, Lacasse Y, Shader RI: Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacology 73: 381–383, 1981.
Cowan PJ, Nutt DJ: Abstinense symptoms after withdrawal of tranquilizing drugs: is there a common mechanism? Lancet 2: 360–362, 1982.
Baselt RC, Cravey RH: A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids. J Analyt Toxicol 1: 81–103, 1977.
Aderjan R, Mattern R: Eine toedlich verlaufene monintoxikation mit flurazepam (Dalmadorm). Arch Toxicol 43: 69–75, 1979.
Ferrara SD, Tedeschi L, Marigo M, Castagna F: Concentrations of phenobarbital, flurazepam, and flurazepam metabolites in autopsy cases. J For Sci 24: 61–69, 1979.
Ruff RL, Kutt H, Hafler D: Prolonged benzodiazepine coma. NY State J Med 81: 776–777, 1981.
Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249: 1452–1454, 1983.
Allen MD, Greenblatt DJ, Lacasse Y, Shader RI: Pharmacokinetic study of lorazepam overdosage. Am J Psychiatr 137: 1414–1415, 1980.
Jeffrey DI, Whitfield MF: Lorazepam poisoning. Br Med J 4: 719, 1974.
Vlachos P, Kentarchou P, Poulos L, Aloupogiannis G: Lorazepam poisoning. Tox Lett 2: 109–110, 1978.
Matthew H, Proudfoot AT, Aitken RCB, et al.: Nitrazepam—a safe hypnotic. Br Med J 3: 23–25, 1969.
Adelstein AM: Safety of nitrazepam [Letter]. Lancet 1: 933–934, 1974.
Oliver JS, Smith H: Determination of nitrazepam in poisoning cases. For Sci 4: 183–186, 1974.
Torry JM: A case of suicide with nitrazepam and alcohol. Practitioner 217: 648–649, 1976.
Bardhan KD: Cerebellar syndrome after nitrazepam overdosage. Lancet 1: 1319–1320, 1969.
Shimkin PM, Shaivitz SA: Oxazepam poisoning in a child. JAMA 196: 662–663, 1966.
Zileli MMS, Teletar F, Deniz S, et al.: Oxazepam intoxication simulating non-keto-acidotic diabetic coma. JAMA 215: 1986, 1971.
Product information, Upjohn Company, 1982.
Trappier B, Bezeredi T: Triazolam intoxication. Can Med Assoc J 126: 893–894, 1982.
Martin FIR, Hansen N, Warn GL: Attempted suicide by insulin overdose in insulin requiring diabetics. Med J Austral 1: 58–60, 1977.
Sturner WQ, Putnam RS: Suicidal insulin poisoning with nine day survival: recovery in bile at autopsy by radioimmunossay. J For Sci 9: 37–42, 1977.
Brikinshaw VJ, Gurd MR, Randall SS, et al.: Investigations in a case of murder by insulin poisoning. Br Med J 2: 463–468, 1958.
Bauman WA, Yalow RS: Insulin as a lethal weapon. J For Sci 26: 594–598, 1981.
Bobzien WF: Suicidal overdoses with hypoglycemic agents. J Coll Emer Phy 8: 467–470, 1979.
Seltzer HS: Drug-induced hypoglycemia-a review based on 473 cases. Diabetes 21: 955–966, 1972.
Alexander RW: Prolonged hypoglycemia following acetohexamine administration. Diabetes 15: 362, 1966.
Dougherty, J: Hypoglycemic stupor caused by acetohexamide. N Engl J Med 274: 1256–1258, 1966.
Cowen DL, Burtis B, Youmans J: Prolonged coma after acetohexamide ingestion. JAMA 201: 155–156, 1967.
Lampe WT: Hypoglycemia due to acetohexamide. Arch Intern Med 120: 239–241, 1967.
Skoutakis VA, Black WD, Acchiardo SR, Wood GC: Peritoneal dialysis in the treatment of acetohexamide-induced hypoglycemia. Am J Hosp Pharm 34: 68–70, 1977.
Agarwal RC, Kumar D, Miller LV: Chlorpropamide-induced hypoglycemia. Diabetes 19: 376, 1970.
Levin EB: Severe hypoglycemic reaction with chlorpropamide in therapeutic dosage. Calif Med 98: 279, 1963.
Sackner MA, Balian LJ: Permanent brain damage secondary to the ingestion of chlorpropamide. Am J Med 28: 125, 1960.
Graw RG: Chlorpropamide intoxication—treatment with peritoneal dialysis. Pediatrics 45: 106–109, 1970.
Dowell RC, Imrie AH: Chlorpropamide poisoning in non-diabetics. Scot Med J 17: 305–309, 1972.
Johnson SF, Schade DS, Peake GT: Chlorproamide-induced hypoglycemia. Am J Med 63: 799–804, 1977.
Sillence DO, Court JM: Glibenclamide-induced hypoglycemia. Br Med J 3: 490–491, 1975.
Pavone L, Mollica F, Mususemici S, et al.: Accidental glibenclamide ingestion in an infant: clinical and encephalographic aspects. Dev Med Child Neurol 22: 366–371, 1980.
Kullavanijaya P: Recovery from overdose of glibenclamide. Br Med J 4: 53–54, 1970.
Ahlquist DA, Nelson RL, Callaway CW: Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 93: 281–282, 1980.
Cosnett JE: Tolbutamide overdosage and irreversible cerebral damage. South Afr Med J 35: 43–44, 1961.
Forrest JAH: Clorpropamide overdosage: delayed and prolonged hypoglycemia. Clin Toxicol 7: 19–24, 1974.
Mari G, Cozzolino G, Palumbo R: Glucagon in sulfonylurea hypoglycemia. Lancet 1: 303, 1968.
Altszuler N, Hampshire J, Morarv E: On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26: 931–935, 1977.
Balsam MJ, Baker L, Bishop HC, et al.: Beta cell adenoma in a child with hypoglycemia controlled with diazoxide. J Ped 80: 788–795, 1972.
Pert CB, Snyder SH: Opiate receptor: demonstration in nervous tissue. Science 179: 1011–1014, 1973.
Martin WR: Naloxone. Ann Intern Med 85: 765–768, 1976.
Jaffe JH, Martin WR: Opioid analgesics and antagonists, Chapter 22. In Goodman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, pp 494–534, 1980.
Gilbert PE, Martin WR: Antagonism of the convulsant effects of heroin, d-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice. J Pharmacol Exp Ther 192: 538–541, 1975.
Snyder SH, Pert CB, Pasternak GW. The opiate receptor. Ann Intern Med 81: 534–540, 1974.
Jhamandas K, Phillis JW, Pinsky C: Effects of narcotic analgesics and antagonists on the in vivo release of acetylcholine from cerebral cortex of the cat. Br J Pharmacol 43: 53–66, 1971.
Snyder SH: The opiate receptor and morphine-like peptides in the brain. Am J Psychiatr 135: 645–652, 1978.
Sharma SK, Klee WA, Nirenberg M: Dual regulation of adenyl cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci 72: 3092–3096, 1975.
Florez J, McCarthy LE, Borison HL: A comparative study in the cat of the respiratory effects of morphine injected intravenously and into the cerebrospinal fluid. J Pharmacol Exp Ther 163: 448–455, 1968.
Eckenhoff JE, Oesch SR: The effects of narcotics and antagonists upon respiration and circulation in man. Clin Pharm Ther 1: 483–524, 1960.
Tommisto T, Jaattela A, Nikki P, Takki S: Effect of pentazocine and pethidine on plasma catecholamine levels. Ann Clin Res 3: 22–29, 1971.
Labi M: Paroxysmal atrial fibrillation in heroin intoxication. Ann Intern Med 71: 951–959, 1969.
Abramson DH: Bigeminy and heroin intoxication. NY State J Med 72: 2888–2890, 1972.
Lee HK, Wang SC: Mechanism of morphine induced miosis in the dog. J Pharmacol Exp Ther 192: 415–431, 1975.
Muhlendahl KE, Krienke EG, Scherf-Rahne B, Baukloh G: Codeine intoxication in childhood. Lancet 2: 303–305, 1976.
Rupreht J, Dwaracek B, Oosthoek H, Dzoljic MR, Valkenburg M: Physostigmine versus naloxone in heroin overdose. Clin Toxicol 21: 387–397, 1984.
Riding JE, Robinson JS: The safety of neostigmine. Anaesthesia 16: 346–354, 1961.
Klock JC, Sexton MJ: Rhabdomyolysis and acute myoglobinuric renal failure following heroin use. Calif Med 119: 5–8, 1973.
Schwartzfarb L, Singh G, Marcus D: Heroin-associated rhabdomyolysis with cardiac involvement. Arch Intern Med 137: 1255–1257, 1977.
Katz S, Aberman A, Frand UI, et al.: Heroin pulmonary edema, evidence for increased capillary permeability. Am Rev Resp Dis 106: 472–474, 1972.
Steinberg AD, Karliner JS: The clinical spectrum of heroin pulmonary edema. Arch Intern Med 122: 122–127, 1968.
Berry YJ: Cough-medicine “highs.” N Engl J Med 295: 286–287, 1976.
Dunne JW: Drug smuggling by internal bodily concealment. Med J Austral 2: 436–439, 1983.
Paranthanan SK, Kahn F: Acute cardiomyopathy with recurrent pulmonary edema and hypotension following heroin overdosage. Chest 69: 117–119, 1976.
Baselt RC, Allison DJ, Wright JA, et al.: Acute heroin fatalities in San Francisco—demographic and toxicologic characteristics. West J Med 122: 455–458, 1975.
Huber DH, Stiver RR, Howard LB: Heroin-over- dose deaths in Atlanta. JAMA 228: 319–322, 1974.
Richards RG, Reed D, Cravey RH: Death from intravenously administered narcotics: a study of 114 cases. J For Sci 21: 467–482, 1976.
Duberstein JL, Kaufman DM: A clinical study of an epidemic of heroin intoxication and heroin- induced pulmonary edema. Am J Med 51: 704–714, 1971.
Nakamura GR, Griesemer EC, Noguchi TT: Antemortem conversion of codeine to morphine in man. J For Sci 21: 518–524, 1976.
Sklar J, Timms RM: Codeine-induced pulmonary edema. Chest 72: 230–231, 1977.
Huffman DH, Ferguson RL: Acute codeine overdose: correspondence between clinical course and codeine metabolism. Johns Hopkins Med J 136: 183–186, 1975.
Wright JA, Baselt RC Hine CH. Blood codeine concentrations in fatalities associated with codeine. Clin Toxicol 8: 457–463, 1975.
Peat MA, Sengupta S: Toxicological investigations of cases of death involving codeine and dihydrocodeine. For Sci 9: 21–32, 1977.
Person MA, Poklis A, Morrison RR: A fatality due to the ingestion of (methyl morphine) codeine. Clin Toxicol 15: 267–271, 1979.
Inturrisi CE, Verebely K: Disposition of methadone in man after a single oral dose. Clin Pharm Ther 13: 923–930, 1972.
Inturrisi CE, Verebely K: The levels of methadone in the plasma in methadone maintenance. Clin Pharm Ther 13: 633–637, 1972.
Olsen GD: Methadone binding to human plasma protein. Clin Pharm Ther 14: 338–343, 1973.
Aronow R, Brenner SL, Wooley PV: An apparent • epidemic: methadone poisoning in children. Clin Toxicol 6: 175–182, 1973.
Smialek JE, Monforte JR, Aronow R, Spitz WU: Methadone deaths in children. JAMA 238: 2516–2517, 1977.
Garriott JC, Sturner WQ, Mason MF: Toxicologic findings in six fatalities involving methadone. Clin Toxicol 6: 163–173, 1973.
Greene MH, Luke JL, DuPont RL: Opiate overdose deaths in the District of Columbia. Part II. Methadone-related fatalities. J For Sci 19: 575–584, 1974.
Waldron VD, Klimt CR, Seibel JE: Methadone overdose treated with naloxone infusion. JAMA 225: 53, 1973.
Gram LF, Schou J, Way WL, et al.: d-Propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharm Ther 26: 473–482, 1979.
McMahon RE, Ridolfo AS, Culp HW, et al.: The fate of radiocarbon-labelled propoxyphene in rat, dog, and human. Tox Appl Pharm 19: 427–444, 1971.
Qureshi E: Propoxyphene hydrochloride poisoning. JAMA 185: 470–471, 1964.
Heaney RM: Left bundle branch block associated with propoxyphene hydrochloride poisoning. Ann Emerg Med 12: 780–782, 1983.
Gustafson A, Gustafson B: Acute poisoning with dextropropoxyphene. Acta Med Scand 200: 241–248, 1976.
Fisch HP, Wands J, Yeung J, Davis PJ: Pulmonary edema and disseminated intravascular coagulation after intravenous abuse of d-propoxyphene (Darvon). South Med J 65: 493–495, 1972.
Young DJ: Propoxyphene suicides—report of nine cases. Arch Intern Med 129: 62–66, 1972.
Sturner WQ, Garriott JC: Deaths involving pro-poxyphene. A study of 41 cases over a two-year period. JAMA 223: 1125–1130, 1973.
Szeto HH, Inturrisi CE, Houde R, et al.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure and cancer. Ann Intern Med 86: 738–741, 1977.
Siek TJ: The analysis of meperidine and normeperidine in biological specimens. J For Sci 23: 6–13, 1978.
Information from manufacturer, Winthrop Company, 1984.
Ford GC, Haskins NJ, Palmer RF, et al.: The measurement of diphenoxylic acid in plasma following administration of diphenoxylate. Biomed Mass Spec 3: 45–47, 1976.
Karim A, Ranney RE, Eversen KL, Clark ML: Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharm Ther 13: 407–419, 1972.
Henderson W, Psaila A: Lomotil poisoning. Lancet 1: 307–308, 1969.
Harris JT, Rossiter M: Fatal lomotil poisoning. Lancet: 1: 150, 1969.
Rumach BH, Temple AR: Lomotil poisoning. Pediatrics 53: 495–500, 1974.
Amment ME: Diphenoxylate poisoning in children. J Ped 74: 462–464, 1969.
Riley ID: Lomotil poisoning. Lancet 1: 374, 1969.
Curtis JA, Goel KM: Lomotil poisoning in children. Arch Dis Child 54: 222–225, 1979.
Information from manufacturer, Searle Company, 1984.
Brown JW: Toxic megacolon associated with loperamide therapy. JAMA 241: 501–502, 1979.
Information from manufacturer, Janssen Company, 1984.
Marcovitch H: Loperamide in toddler diarrhea. Lancet 1: 1413, 1980.
Friedli G, Haenggeli CA: Loperamide overdose managed by naloxone. Lancet 1: 1413, 1980.
Hunter R, Ingram IM: Intravenous pentazocine abuse by a nurse. Lancet 2: 227, 1983.
Stahl SM, Kasser IS: Pentazocine overdose. Ann Emerg Med 12: 28–31, 1983.
Showalter CV: T’s and blues—abuse of pentazocine and tripelennamine. JAMA 244: 1224–1225, 1980.
DeBard ML, Jagger JA: “T’s and blues”—midwestern heroin substitute. Clin Toxicol 18: 1117–1123, 1981.
Butch AJ, Yokel RA, Sigell LT, et al.: Abuse and pulmonary complications of injecting pentazocine and tripelennamine tablets. Clin Toxicol 14: 301–306, 1979.
Information from manufacturer, Bristol Company, 1984.
Gaver RC, Vasijev M, Wong H, et al.: Disposition of parenteral butorphanol in man. Drug Met Disp 8: 230–235, 1980.
Information from manufacturer, Du Pont Company, 1984.
Westfall TC: Local regulation of adrenergic transmission. Physiol Rev 57: 659–728, 1977.
Goldberg MR, Robertson D: Yohimbine: a pharmacological probe for study of the alpha-2 adrenoceptor. Pharmacolog Rev 35: 143–180, 1983.
Hoffman BB, Lefkowitz RJ: Alpha-adrenergic receptor subtypes. New Engl J Med 302: 1390–1391, 1980.
McGrath JC: Evidence for more than one type of postjunctional alpha adrenoceptor. Biochem Pharmacol 31: 467–484, 1982.
Nwanze E, Jonsson G: Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice [Letter]. Neuroscience 26: 163–168, 1981.
Trulson ME, Jacobs BL: Long-term amphetamine treatment decreases brain serotonin metabolism: implications for theories of schizophrenia. Science 205: 1295–1297, 1979.
Wagner GC, Ricaurte GA, Johnson CE, Schuster CR, Seiden LS: Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 30: 547–550, 1980.
Ginsberg MD, Hertzman M, Schmidt-Nowara WW: Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. Ann Intern Med 73: 81–85, 1970.
Harrington H, Heller A, Dawson D, et al.: Inter- cerebral hemorrhage and oral amphetamine. Arch Neurol 40: 503–507, 1983.
Delaney P, Estes M: Intracranial hemorrhage with amphetamine abuse. Neurology 30: 1125–1128, 1980.
Citron BP, Halpern M, McCarron MM, et al.: Necrotizing angiitis associated with drug abuse. N Engl J Med 283: 1003–1011, 1970.
Matick H, Anderson D, Brumlik J: Cerebral vasculitis associated with oral amphetamine overdose. Arch Neurol 40: 253–254, 1983.
Eplin DE, Done AK: Amphetamine poisoning, effectiveness of chlorpromazine. N Engl J Med 278: 1361–1365, 1968.
Gary NE, Saidi P: Methamphetamine intoxication—a speedy new treatment. Am J Med 64: 537–540, 1978.
Catravas JD, Waters IW, Hickenbottom JP, Davis WM: The effects of haloperidol, chlorpromazine and propranolol on amphetamine poisoning in the conscious dog. J Pharmacol Exp Ther 202: 230–243, 1977.
Davis WM, Logston DG, Hickenbottom JP: Antagonism of acute amphetamine intoxication by haloperidol and propranolol. Toxicol Appl Pharmacol 29: 397–403, 1974.
Wallace HE, Neumayen F, Gutch CE: Amphetamine poisoning and peritoneal dialysis. Am J Dis Child 108: 657–661, 1964.
Winchester JF, Gelfand MC, Knepshield JH, Schreiner GE: Dialysis and hemoperfusion of poisons and drugs—update. Trans Am Soc Artif Intern Organs 23: 762–842, 1977.
Gericke OL: Suicide by ingestion of amphetamine sulphate. JAMA 128: 1098–s1099, 1945.
Keiter WE, Arnold JH: Acute dexedrine intoxication in children. Arch Ped 72: 126–128, 1955.
Patuck D: Acute dextroamphetamine poisoning in a child. Br Med J 1: 670–671, 1956.
Ong BH: Dextroamphetamine poisonings. N Engl J Med 266: 1321–1322, 1962.
DiMaio VJM, Garriott JC: Death due to ingestion of dextroamphetamine. For Sci Gaz 8: 1–2, 1977.
Cravey RH, Baselt RC: Methamphetamine poisoning. J For Sci Soc 8: 118–120, 1968.
Zalis EG, Parmley LF Jr: Fatal amphetamine poisoning. Arch Intern Med 112: 822–826, 1963.
Cravey RH, Reed D: Intravenous amphetamine poisoning: report of three cases. J For Sci Soc 10: 109–112, 1970.
Hall CD, Blanton DE, Scatliff JH, Morris CE: Speed kills: fatality from the self-administration of methamphetamine intravenously. South Med J 66: 650–652, 1973.
Norheim G: A fatal case of phenmetrazine poisoning. J For Sci Soc 13: 287–289, 1973.
Hamer R, Phelps D: Inadvertent intra-arterial injection of (phenmetrazine)—a complication of drug abuse. Ann Emerg Med 10: 148–150, 1981.
Kendrick WC, Hull AR, Knochel JP: Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 86: 381–387, 1977.
Rubin RT: Acute psychotic reaction following ingestion of phentermine. J Psychiatr 120: 1124, 1964.
Pentel P: Toxicity of over-the-counter stimulants. JAMA 252: 1898–1903, 1984.
Dietz AJ: Amphetamine-like reactions to phenyl-propanolamine. JAMA 245: 601–602, 1981.
Mesnard B, Ginn DR: Excessive phenypropanolamine ingestion followed by subarachnoid hemorrhage. South Med J 77: 939, 1984.
Nakamura GR, Noguchi TT: Fatalities from cocaine overdoses in Los Angeles County. Clin Toxicol 18: 895–905, 1981.
Wetli CV, Mittleman RE: The “body packer” syndrome: toxocity following ingestion of illicit drugs packed for transportation. J For Sci 26: 492–500, 1981.
Coleman DL, Ross TF, Naughton JL: Myocardial ischemia and infarction related to recreational cocaine use. West J Med 136: 444–446, 1982.
Acker D, Sachs BP, Tracey KJ, Wise WE: Abruptio placentae associated with cocaine use. Am J Obstet Gynecol 146: 220–221, 1983.
Sharif JA: Renal infarction associated with intravenous cocaine use. Ann Emerg Med 13: 1145–1147, 1984.
Shesser R, Davis C, Edelstein S: Pneumomediastinum and pneumothorax after inhaling alkaloidal cocaine. Ann Emerg Med 10: 213–215, 1981.
Allred RJ, Ewer S: Fatal pulmonary edema following intravenous “free base” cocaine use. Ann Emerg Med 10: 441–442, 1981.
Sinner WN: The gastrointestinal tract as a vehicle for drug smuggling. Gastrointest Radiol 6: 319–323, 1981.
McCarron MM, Wood JD: The cocaine “body packer” syndrome—diagnosis and treatment. JAMA 250: 1417–1420, 1983.
Freed TA, Sweet LN, Gauder PJ: Balloon obturation bowel obstruction: a hazard of drug smuggling. Am J Roentgenol 127: 1033–1034, 1976.
Suarez CA, Arango A, Lester JL III: Cocaine-condom ingestion: Surgical treatment. JAMA 238: 1391–1392, 1977.
Bettinger J: Cocaine intoxication: massive oral overdose. Ann Emerg Med 9: 429–430, 1980.
Jonsson S, O’Meara M, Young JB: Acute cocaine poisoning. Am J Med 75: 1061–1064, 1983.
Orr D, Jones I: Anesthesia for laryngoscopy. A comparison of the cardiovascular effects of cocaine and lignocaine. Anaesthesia 23: 194–202, 1968.
Benchimol A, Bartall H, Desser KB: Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 88: 519–520, 1978.
Gay GR: Clinical management of acute and chronic cocaine poisoning Ann Emerg Med 11: 562–572, 1982.
Catravas JD, Waters IW, Walz MA, Davis WM: Antidotes for cocaine poisoning. New Engl J Med 297: 1238, 1977.
Bulletin of Poisindex, Drugdex, Emergindex Editorial Board: Yohimbine—an abused drug. Rocky Mountain Poison and Drug Center, Denver, Colorado, Apr, 1984.
Scatton B, Zivkovic B, Dedek J: Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215: 494–499, 1980.
Boyd H, Chang V, Rand MJ: The anticholinesterase activity of some antiadrenaline agents. Br J Pharmacol 15: 525–531, 1960.
Freed WJ, Weinberger DR, Bing LA, Wyatt RJ: Neuropharmacological studies of phencylidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology 71: 291–297, 1980.
Lambert GA, Lang WJ: Interaction between yohimbine alkaloids and amphetamine in mice. Psychopharmacology 51: 209–212, 1977.
Morales A, Surridge DHC, Marshall PG, Fenemore J: Nonhormonal pharmacological treatment of organic impotence. J Urol 128: 45–47, 1982.
Steers WD, McConnell J, Benson GS: Some pharmacologic effects of yohimbine on human and rabbit penis. Pharamcolog Rev 36: 799–802, 1984.
Sokolovsky M: Muscarinic receptors in the central nervous system. Int Rev Neurobiol 25: 139–183, 1984.
White P, Hiley CR, Goodhardt MJ, et al.: Neocortical cholinergic neurons in elderly people. Lancet 1: 668–670, 1977.
Longo VG: Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev 18: 965–996, 1966.
Gillick JS: Atropine toxicity in a neonate. Br J Anaesth 46: 793–794, 1974.
Mikolich JR, Paulson GW, Cross CJ: Acute anticholinergic syndrome due to jimson weed ingestion. Ann Intern Med 83: 321–325, 1975.
Hall RCW: Angel’s trumpet psychosis: a central nervous system anticholinergic syndrome. Am J Psychiatr 134: 312–314, 1977.
Information from manufacturer, O’Neal, Jones and Feldman Co.
Levy R: Arrhythmias following physostigmine administration in jimson weed poisoning. J Am Coll Emerg Phys 6: 107, 1977.
Gosselin RE, Gabourel JD, Wills JH: The fate of atropine in man. Clin Pharmacol Ther 1: 597–603, 1960.
Kaiser SC: The fate of atropine in man. Ann NY Acad Sci 179: 667–683, 1971.
Baker JP, Farley JD: Toxic psychosis following atopine eye drops. Br Med J 2: 1390–1392, 1958.
Hoefnagel D: Toxic effects of atropine and homatropine eyedrops in children. New Engl J Med 264: 168–171, 1961.
German E, Siddiqui N: Atropine toxicity from eyedrops. New Engl J Med 282: 689, 1970.
Hoffman GM, Gay JR: Atropine in an unusual case of poisoning. Pa Med 62: 1340–1341, 1959.
Beatson N: Atropine and paralytic ileus. Postgr Med J 58: 451–453, 1982.
Heath WE: Death from atropine poisoning. Br Med J 2: 608, 1950.
Comroe BI: Atropine poisoning: recovery after 71/2 grains of atropine sulphate by mouth. JAMA 101: 446–447, 1933.
Rubinstein JS: Abuse of antiparkinsonism drugs. JAMA 239: 2365–2366, 1978.
Pakes GE: Abuse of trihexyphenidyl. JAMA 240: 2434, 1978.
Craig DH, Rosen P: Abuse of antiparkinsonian drugs. Ann Emerg Med 10: 98–100, 1981.
Dollery CT, Davies DS, Draffan GH, et al.: Clinical pharmacology and pharmokinetics of Clonidine. Clin Pharm Ther 19: 11–17, 1976.
Davies DS, Wing LMH, Reid JL, et al.: Pharmokinetics and concentration-effect relationships of in¬travenous and oral Clonidine. Clin Pharm Ther 21: 593–601, 1977.
Kobinter W: Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 81: 40–100, 1978.
Isaac L: Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol 2(Suppl): S5–S19, 1980.
Wing LMH, Redi JL, Davies DS, et al.: Pharmacokinetic and concentration-effect relationships of Clonidine in essential hypertension. Eur J Clin Pharm 12: 463–469, 1977.
Hunyor SN, Bradstock K, Somerville PJ, et al.: Clonidine overdose. Br Med J 4: 23, 1975.
Stein B, Volans GN: Dixarit overdose: the problem of attractive tablets. Br Med J 2: 667–668, 1978.
Saperia J: Clonidine overdose. Br Med J 4: 580, 1975.
Poyner TF, Gennery BA, Vasey RH: Management in cases of Clonidine overdosage. Practitioner 217: 132–134, 1976.
Pai GA, Lipstiz DJ: Clonidine poisoning in children. Lancet 1: 1266–1267, 1977.
Moore MA, Phillipi P: Clonidine overdose. Lancet 2: 694, 1976.
Artman M, Boerth RC: Clonidine poisoning. Am J Dis Child 137: 171–174, 1983.
Mofenson HC, Greensher J, Weiss TE: Clonidine poisoning: is there a single antidote? Clin Toxicol 14: 271–275, 1979.
Anderson RJ, Hart GR, Crumpler CP, Lerman MJ: Clonidine overdose: report of six cases and review of the literature. Ann Emerg Med 10: 107–112, 1981.
Neuvonen PJ, Vilska J, Keranen A: Severe poisoning in a child caused by a small dose of Clonidine. Clin Toxicol 14: 369–374, 1979.
Olsson JM, Pruitt AW: Management of Clonidine ingestion in children. J Ped 103: 646–650, 1983.
Kulig K, Duffy J, Rumack BH, et al.: Naloxone for treatment of Clonidine overdose. JAMA 247: 1697, 1982.
Banner W, Lund ME, Clawson L: Failure of naloxone to reverse Clonidine toxic effect. Am J Dis Child 137: 1170–1171, 1983.
Rotellar JAO, Monasterio ES, Gene CG: Clonidine in thousand-fold overdose. Lancet 1: 1312, 1981.
Robertson D, Frölich JC, Carr RK, et al.: Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 298: 181–186, 1978.
Gilman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th Ed. Macmillan Publishing Co Inc, New York, 1980.
Katz AM, Repke DI, Haselbach W: Dependence of ionophore-and caffeine-induced calcium release from sarcoplasmic reticulum vesicles on external and internal calcium ion concentrations. J Biol Chem 252: 1938–1949, 1977.
Mitenko PA, Ogilvie RI: Rapidly achieved plasma concentration plateaus, with observations on theophylline kinetics. Clin Pharm Ther 13: 329–335, 1972.
Lillehei JP: Aminophylline—oral vs rectal administration. JAMA 205: 530–533, 1968.
Grygiel J, Birkett DJ: Effect of age on patterns of theophylline metabolism. Clin Pharm Ther 28: 456–462, 1980.
Bukowskyj M, Nakatsu K, Munt PW: Theophylline reassessed. Ann Intern Med 101: 63–73, 1984.
Nakada T, Kwee IL, Lerner AM, Remler MP: Theophylline-induced seizures: clinical and pathological aspects. West J Med 138: 371–374, 1983.
Vincent FM: Fatal theophylline-induced seizures. Postgr Med J 6: 76–77, 1978.
Winke CL, Bricker JD, Collom WD, Fochtman FW: Theophylline fatalities. For Sci Int 15: 233–236, 1980.
Anderson JR, Poklis A, Slavin RG: A fatal case of theophylline intoxication. Arch Intern Med 143: 559–560, 1983.
Park GD, Spector R, Roberts RJ, et al.: Use of hemoperfusion for treatment of theophylline intoxication. Am J Med 74: 961–966, 1983.
Addiction Research Foundation of Ontario: Facts about caffeine. Toronto, Canada, Jan 1981.
Turner JE, Cravey RH: A fatal ingestion of caffeine. Clin Toxicol 10: 341–344, 1977.
Sullivan JL: Caffeine poisoning in an infant. J Ped 90: 1022–1023, 1977.
Boyd EM: The acute oral toxicity of caffeine. Toxicol Appl Pharmacol 1: 250–257, 1959.
May DC, Long T, Madden R, et al.: Caffeine toxicity secondary to street drug ingestion. Ann Emerg Med 10: 549, 1981.
Benowitz NL, Osterloh J, Goldschlager N, et al.: Massive catecholamine release from caffeine poisoning. JAMA 248: 1097–1098, 1982.
Bernstein E, Diskant BM: Phenylpropanolamine: a potentially hazardous drug. Ann Emerg Med 11: 311–315, 1982.
Swenson RD, Golper TA, Bennett WM: Acute renal failure and rhabdomyolysis after ingestion of phenylpropanolamine-containing diet pills. JAMA 248: 1216, 1982.
Howrie DL, Wolfson JH: Phenylpropanolamine- induced hypertensive seizures. J Ped 102: 143–145, 1983.
Bale JF, Fountain T, Shaddy R: Phenylpropanola- mine-associated CNS complications in children and adolescents. Am J Dis Child 138: 683–685, 1984.
Weesner KM, Denison M, Roberts RJ: Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. Clin Ped 21: 700–701, 1982.
Heath A: Beta-adrenoceptor blocker toxicity: clinical features and therapy. Am J Emerg Med 2: 518–525, 1984.
Glick G, Parmly WW, Wecksler AS, et al.: Glucagon: its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta receptor blockade with propranolol. Circ Res 22: 789–799, 1968.
Illingworth RN: Glucagon for beta-blocker poisoning. Practitioner 223: 683, 1979.
Rosa RM, Silva P, Young JB, Landsberg L, et al.: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302: 431, 1980.
Information from manufacturer, Stuart Company.
Kirch W, Koehler H, Mutschier E, Schaefer M: Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharm 19: 65–71, 1981.
Shanahan FLJ, Counihan TB: Atenolol self poisoning. Br Med J 2: 773, 1978.
Moller BHJ: Massive intoxication with metoprolol. Br Med J 24: 222, 1976.
Stajic M, Granger RH, Beyer JC: Fatal metoprolol overdose. J Analyt Toxicol 8: 228–230, 1984.
Sire S: Metoprolol intoxication. Lancet 2: 1137, 1976.
Shore ET, Cepin D, Davidson MJ: Metoprolol overdose. Ann Emerg Med 10: 524–527, 1981.
Holzbecker M, Perry RA, Ellenberger HA: Report of a metoprolol associated death. J For Sci 27: 715–717, 1982.
Information from manufacturer, Sandoz Pharmaceuticals, 1984.
Wermut W, Wojcicki M: Suicidal attempt with propranolol. Br Med J 3: 591, 1973.
Turner JE, Cravey RH: A fatal case involving propranolol and codeine. Clin Toxicol 8: 271–275, 1975.
Gault R, Monforte JR, Khasnabis S: A death involving propranol (Inderal). Clin Toxicol 11: 295–299, 1977.
Kristinsson J, Johnannesson J: A case of fatal propranolol intoxication. Acta Pharm Tox 41: 190–192, 1977.
Information from manufacturer, Merck Company, 1984.
Elliott J: Consensus on amantadine use in influenza A [Medical News] JAMA 242: 2383–2387, 1979.
Grelak RP, Clark R, Stump JM, et al.: Amantadine-dopamine interaction: possible mode of action in parkinsonism. Science 169: 203–204, 1970.
Information from manufacturer, Du Pont Company, 1984.
Ing TS, Rahn AC, Armbruster KFW, et al.: Accumulation of amantadine hydrochloride in renal insufficiency. N Engl J Med 291: 1257, 1974.
Fahn S, Craddock G, Kumin G: Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 25: 45–48, 1971.
Sartori M, Pratt CM, Young JB: Torsade de Pointe—malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 77: 388–391, 1984.
Casey DE: Amantadine intoxication reversed by physostigmine. New Engl J Med 298: 516, 1978.
Berkowitz CD: Treatment of acute amantadine toxicity with physostigmine. J Ped 95: 144–145, 1979.
Green JP, Johnson CL, Weinstein H: Histamine as a neurotransmitter. In Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: a generation of progress. Raven Press, New York, pp 319–332, 1978.
Schwartz JC: Histaminergic mechanisms in brain. Ann Rev Pharmacol Toxicol 17: 325–339, 1977.
Information from manufacturer, Parke-Davis Company, 1984.
Information from manufacturer, Smith Kline Company, 1984.
Shaw RG, Mashford ML, Desmond PV: Cardiac arrest after intravenous injection of Cimetidine. Med J Austral 2: 629–630, 1980.
King AR: Cardiac arrest and Cimetidine. Med J Austral 1: 139, 1981.
Kato H, Kurihara J, Kasuya Y: Cardiovascular effects of Cimetidine. Arch Intern Pharmacodyn 249: 247–256, 1981.
Hiss J, Hepler BR, Falkowski A J, Sunshine I: Fatal bradycardia after intentional overdose of cimeti- dine and diazepam. Lancet 2: 982, 1982.
Pizzella LM, Moore MC, Schulz RW, et al.: Removal of cimetidine by peritoneal dialysis, hemodialysis and charcoal hemoperfusion. Ther Drug Mon 2: 273–281, 1980.
Pahnke WN, Jurland AA, Unger S, Savage C, Grof S: The experimental use of psychedelic (LSD) psychotherapy. JAMA 212: 1856–1863, 1970.
Gilman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, 1980.
Gosslin RE, Hodge HC, Smith RP, Gleason MN: Clinical toxicology of commercial products, 4th ed. Williams and Wilkins Co, Baltimore, 1976.
Feldberg W: The monoamines of the hypothalamus as mediators of temperature responses. In Robson JM, Stacey RS (eds): Recent advances in pharmacology, 4th ed. J & A Churchill, Ltd, London, 1968.
Feldberg W, Sherwood SL: Injections of drugs into the lateral ventricle of the cat. J Physiol (London) 123: 148–167, 1954.
Born GVR, Michal F: 5-Hydroxytryptamine receptors on platelets. Biochemistry and pharmacology of platelets. Ciba Symposium, vol 35. Amsterdam, 1975.
Schwarz BE, Bickford RB: Reversibility of induced psychosis with chlorpromazine. Proc Staff Meet Mayo Clin 30: 407–417, 1955.
Solursh LP, Clement WR: Use of diazepam in hallucinogenic drug crises. JAMA 205: 98–99, 1968.
Horowitz MJ: Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatr 126: 565–569, 1969.
Friedman SA, Hirsch SE: Extreme hyperthermia after LSD ingestion. JAMA 217: 1549–1550, 1971.
Klock JC, Boerner U, Becker CE: Coma, hyperthermia and bleeding associated with massive LSD overdose. West J Med 120: 183–188, 1974.
Ingram AL: Morning glory seed reaction. JAMA 190: 1133–1134, 1964.
Cohen S: Suicide after ingestion of morning glory seeds. Am J Psychiatr 120: 1024–1025, 1964.
Fink PJ, Goldman MJ, Lyons I: Morning glory seed psychosis. Arch Gen Psychiatr 15: 209, 1966.
Dewhurst K: Psilocybin intoxication. Br J Psych 137: 303–304, 1980.
Young RE, Milroy R, Hutchinson S, Keeson CM: The rising price of mushrooms. Lancet 1: 213–214, 1982.
Snyder SH, Faillace L, Hollister L. 2,5-dimethoxy- 4-methyl-amphetamine (STP): a new hallucinogenic drug. Science 158: 669–670, 1967.
Smith DE: The psychotomimetic amphetamines with special reference to STP (DOM) toxicity. J Psychedel Drugs 2: 75–85, 1969.
Richard KC, Borgstedt HH: Near fatal reaction to ingestion of the hallucinogenic drug MDA. JAMA 218: 1826–1827, 1971.
Finkle BS: MDA death. Bull Int Assoc For Toxicol 6: 4, 1969.
Cimbura G: 3,4-methylenedioxyamphetamine (MDA); analytical and forensic aspects of fatal poisoning. J For Sci 17:329, 1972.
Reed D, Cravey RH, Sedgwick PR: A fatal case involving methylenedioxyamphetamine. Clin Toxicol 5: 3, 1972.
Lukaszewski T: 3,4-Methylenedioxyamphetamine overdose. Clin Toxicol 15:405–409, 1979.
Poklis A, Mackell MA, Drake WK: Fatal intoxica-tion from 3,4- methylenedioxyamphetamine. J For Sci 24: 70, 1979.
Simpson DL, Rumack BH: Methylenedioxyamphetamine: clinical description of overdose, death, and review of pharmacology. Arch Intern Med 141: 1507, 1981.
Cimbura G: PMA deaths in Ontario. Can Med Assoc J 110: 1263–1264, 1974.
Shulgin AT: Chemistry of phenethylamines related to mescaline. J Psychedel Drugs 11: 41, 1979.
Ludwig AM, Levine J: Patterns of hallucinogenic drug abuse. JAMA 191: 104–108, 1965.
Teitelbaum DT, Wingeleth DC: Diagnosis and management of recreational mescaline self poisoning. J Analyt Toxicol 1: 36–37, 1977.
Speck LB: Toxicity and effects of increasing doses of mescaline. J Pharm Exper Ther 119: 78–84, 1957.
Forrest JE, Heacock RA: Nutmeg and mace, the psychotropic spices from Myristica fragrans. Lloydia 35: 440–449, 1972.
Payne RB: Nutmeg intoxication. N Engl J Med 269: 36, 1963.
Celesia G, Messert B, Murphy M: Status epilepticus of late onset. Neurology 22: 1047, 1972.
Kim CH, Perlstein MA: Encephalitis with catatonic schizophrenic symptoms. Illin Med J 138: 503–507, 1970.
Penn H, Racy J, Lapham L, et al.: Catatonic behavior, viral encephalopathy, and death. Arch Gen Psychiatr 27: 758–761, 1972.
Jaffe N: Catatonia and hepatic dysfunction. Dis Ner Syst 28: 606–608, 1967.
Hanson GD, Brown MJ: Waxy flexibility in a post-partum woman: a case report and review of the catatonic syndrome. Psychiatr Q 47: 95–103, 1973.
Thompson GN: Cerebral lesions simulating schizophrenia: three case reports. Biolog Psychiatr 3: 59–64, 1970.
Micheels LJ: Catatonic syndrome in a case of sub-dural hematoma. J Nerv Ment Dis 117: 123–129, 1953.
Hermann M, Harpham D, Rosenblum M: Non- schizophrenic catatonic states. NY State J Med 42: 624, 1942.
Belfer ML, d’Autremont C: Catatonia-like symptomatology. Arch Gen Psychiatr 24: 119–120, 1971.
Murphy JP, Neuman MA: Fatal cerebral vascular accident associated with catatonic schizophrenia. Arch Neurol Psychiatr 49: 724, 1943.
Malamud N, Boyd D: Sudden “brain death” in schizophrenia with extensive lesions in the cerebral cortex. Arch Neurol Psychiatr 41: 352–364, 1939.
Hockaday TD, Keynes WM, McKenzie JK: Catatonic stupor in elderly woman with hyperparathy-roidism. Br Med J 5479: 85–87, 1966.
Lake CR, Fann WE: Possible potentiation of haloperidol neurotoxicity in acute hyperthyroidism. Br J Psych 123: 523–525, 1973.
Katz SE: A catatonic syndrome associated with diabetes mellitus. Arch Neurol Psychiatr 31: 880, 1934.
Schwab J, Barrow MV: A reaction to organic fluo-rides simulating classical catatonia. Am J Psychiatr 120: 1196–1197, 1964.
Gelenberg A J, Mandel MR: Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatr 34: 947–950, 1977.
McCarron MM, Schulze BW, Thompson GA, et al.: Acute phencyclidine intoxication: clinical patterns, complications and treatment. Ann Emerg Med 10: 290–297, 1981.
CarofF SN: The neuroleptic malignant syndrome. J Clin Psychiatr 41: 79–83, 1980.
Simpson DM, Davis GC: Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatr 141: 796–797, 1984.
Eles GR, Songer JE, DiPette DJ: Neuroleptic malignant syndrome complicated by disseminated in-travascular coagulation. Arch Intern Med 144: 1296–1297, 1984.
Hashimoto F, Sherman CB, Jeffery WH: Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intern Med 144: 629–630, 1984.
Coons DJ, Hillman FJ, Marshall RW: Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatr 139: 944–945, 1982.
Goekoop JG, Carbaat PA: Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 2: 49–50, 1982.
May DC, Morris SW, Stewart RM, et al.: Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med 98: 183–184, 1983.
McCarron MM, Boettger ML, Peck JJ: A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatr 43: 381–382, 1982.
Amdurski S, Radwin M, Levi A, Elizur A: A therapeutic trial of amantadine in haloperidol-induced malignant neuroleptic syndrome. Curr Ther Res 33: 225–229, 1983.
Mueller PS, Vester JW, Fermaglieli J: Neuroleptic malignant syndrome—successful treatment with bromocriptine. JAMA 249: 386–388, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
McCarron, M.M. (1986). Diagnosis and Treatment of Drug Overdose. In: Maronde, R.F. (eds) Topics in Clinical Pharmacology and Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4864-4_22
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4864-4_22
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-9336-1
Online ISBN: 978-1-4612-4864-4
eBook Packages: Springer Book Archive